Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154671 | 0.92 | ALDH1A1 (0.50) | CHEK2USP30BTKMEN1KMT2A | |
| SCHEMBL6154090 | 0.88 | GPR119 (0.54) | CHEK2MEN1KMT2AGPR119CNR1 | |
| SCHEMBL6154040 | 0.83 | BTK (0.56) | CHEK2USP30BTKPARP1KMT2A | |
| SCHEMBL6156720 | 0.80 | GPR119 (0.49) | USP30MEN1KMT2AGPR119CNR1 | |
| SCHEMBL22452966 | 0.80 | USP30 (0.44) | USP30BTKMEN1KMT2AHDAC4 | |
| SCHEMBL16901714 | 0.80 | ALOX15 (0.50) | CHEK2USP30BTKPARP1MEN1 | |
| SCHEMBL12279938 | 0.78 | PARP1 (0.49) | CHEK2USP30BTKPARP1HDAC4 | |
| SCHEMBL12280002 | 0.78 | PARP1 (0.49) | CHEK2USP30BTKPARP1HDAC4 | |
| SCHEMBL16791243 | 0.78 | USP30 (0.50) | USP30BTKPARP1KMT2AGPR119 | |
| SCHEMBL16895642 | 0.78 | USP30 (0.50) | USP30BTKPARP1KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | CHEK2 2711/4885USP30 4100/4885BTK 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.